Evidence-based drug policy: It starts with good evidence and ends with policy reform

International Journal of Drug Policy

Volumn 23, Issue 6, 2012, Pages 423-425

  Nosyk, B ^a   Wood, E ^b  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ILLICIT DRUG; METHAMPHETAMINE;

CANNABIS SMOKING; DECISION MAKING; DRUG COST; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG TRAFFIC; DRUG USE; DRUG UTILIZATION; EDITORIAL; EVIDENCE BASED MEDICINE; HEALTH CARE NEED; PRIORITY JOURNAL; QUALITATIVE RESEARCH; QUANTITATIVE ANALYSIS; SOCIAL WELFARE;

COMMERCE; CRIME; DRUG AND NARCOTIC CONTROL; DRUG USERS; GOVERNMENT REGULATION; HUMANS; LAW ENFORCEMENT; POLICY MAKING; PROGRAM DEVELOPMENT; PROGRAM EVALUATION; PUBLIC POLICY; QUALITATIVE RESEARCH; SOCIAL WELFARE; STREET DRUGS; SUBSTANCE-RELATED DISORDERS;

EID: 84869838416     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2012.10.005     Document Type: Editorial

References (29)

1. American Civil Liberties Union. (2012). States take sizable steps in 2012 to end over-incarceration. Accessed 28.09.12. http://www.aclu.org/blog/criminal-law-reform/states-take-sizeable-steps-2012-end-overincarceration.
2. Briggs A.H., Claxton K., Sculpher M.J. Decision modeling for health economic evaluation 2006, Oxford University Press, New York.
3. Campbell H., Hansen T. Getting out of the game: Desistance from drug trafficking. International Journal of Drug Policy 2012, 23(6):481-487.
4. Caulkins J.P., Kilmer B., MacCoun R.J., Pacula R.L., Reuter P. Design considerations for legalizing cannabis: Lessons inspired by analysis of California's Proposition 19. Addiction 2012, 107(5):865-871.
5. Department of Justice Canada. (2012). Backgrounder: Safe Streets and Communities Act. Accessed 28.09.12. http://www.justice.gc.ca/eng/news-nouv/nr-cp/2012/doc_32713.html.
6. Drummond M.F., Sculpher M.J., Torrance G.W., O'Brien B.J., Stoddart G.L. Methods for the economic evaluation of health care programmes 2005, Oxford University Press, New York. 3rd ed.
7. Dunlap E., Graves J., Benoit E. Stages of drug market change during disaster: Hurricane Katrina and reformulation of the New Orleans drug market. International Journal of Drug Policy 2012, 23(6):473-480.
8. Farthing L., Kohl B. Supply-side harm reduction strategies: Bolivia's experiment with social control. International Journal of Drug Policy 2012, 23(6):488-494.
9. Feldman A.M., Serrano R. Welfare economics and social choice theory 2006, 2nd ed.
10. Fernandez M. The socioeconomic impact of drug-related crimes in Chile. International Journal of Drug Policy 2012, 23(6):465-472.
11. Fischer B., Keates A. 'Opioid Drought', Canadian style? Potential implications of the 'natural experiment' of delisting Oxycontin in Canada. International Journal of Drug Policy 2012, 23(6):495-497.
12. Gafni A., Birch S. Incremental cost-effectiveness ratios (ICERs): The silence of the lambda. Social Science and Medicine 2006, 62(9):2091-2100.
13. Global Commission on Drugs. (2011). War on drugs: Report of the Global Commission on Drug Policy. Accessed 28.09.12. http://www.globalcommissionondrugs.org/wp-content/themes/gcdp_v1/pdf/Global_Commission_Report_English.pdf.
14. Hammersvik E., Sandberg S., Pedersen W. Why small-scale cannabis growers stay small: Five mechanisms that prevent small-scale growers from going large-scale. International Journal of Drug Policy 2012, 23(6):458-464.
15. Kilmer, B., Caulkins, J. P., Pacula, R., MacCoun, R. J., & Reuter, P. H. (2010). Altered State? Assessing how marijuana legalization in California could influence marijuana consumption and public budgets. Occasional paper, RAND Drug Policy Research Center. ISBN 978-0-8330-5034-2. Accessed 28.09.12. http://www.rand.org/pubs/occasional_papers/2010/RAND_OP315.pdf.
16. Leoncini R., Rentocchini F. Let it snow! Let it snow! Let it snow! Estimating cocaine production using a novel dataset based on reported seizures of laboratories in Colombia. International Journal of Drug Policy 2012, 23(6):449-457.
17. Nosyk B., Guh D.P., Bansback N.J., Marsh D., Brissette S., Miekleham E., et al. An economic evaluation alongside the North American Opiate Medication Initiative. Canadian Medical Association Journal 2012, 184(6):E317-E328.
18. Ramsey S., Willke R., Briggs A., Brown R., Buxton M., Chawla A., et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value in Health 2005, 8(5):521-533.
19. Reuter P. Why does research have so little impact on American drug policy?. Addiction 2001, 96(3):373-376.
20. Rhodes T., Sarang A., Vickerman P., Hickman M. Policy resistance to harm reduction for drug users and potential effect of change. British Medical Journal 2010, 341:c3439.
21. Rich J.D., Wakeman S.E., Dickman S.L. Medicine and the epidemic of incarceration in the United States. The New England Journal of Medicine 2011, 364(22):2081-2083.
22. Shukla R.K., Crump J.L., Chrisco E.S. An evolving problem: Methamphetamine production and trafficking in the United States. International Journal of Drug Policy 2012, 23(6):426-435.
23. UNODC. (2011). Accessed 28.09.12. http://www.unodc.org/documents/data-and-analysis/WDR2011/World_Drug_Report_2011_ebook.pdf.
24. Van Dun M. The drugs industry and peasant self-defence in a Peruvian cocaine enclave. International Journal of Drug Policy 2012, 23(6):442-448.
25. Werb D., Nosyk B., Kerr T., Fischer B., Montaner J.S.G., Wood E. Estimating the economic value of British Columbia's domestic cannabis market: Implications for provincial cannabis policy. International Journal of Drug Policy 2012, 23(6):436-441.
26. Wood E. Evidence based policy for illicit drugs. British Medical Journal 2010, 341:c3374.
27. Wood E., Werb D., Kazatchkine M., Kerr T., Hankins C., Gorna R., et al. Vienna declaration: A call for evidence-based drug policies. Lancet 2010, 376(9738):310-312.
28. World Health Organization. (2009). Choosing interventions that are cost-effective (WHOCHOICE): Cost-effectiveness thresholds. Accessed 08.09.09. http://www.who.int/choice/costs/CER_thresholds/en/index.html.
29. Zarkin G.A., Dunlap L.J., Hicks K.A., Mamo D. Benefits and costs of methadone treatment: Results from a lifetime simulation model. Health Economics 2005, 14:1133-1150.